Cargando…
E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter
BACKGROUND: Abnormal expression of splicing factor 3A subunit 3 (SF3A3), a component of the spliceosome, has been confirmed to be related to the occurrence and development of various cancers. However, the expression and function of SF3A3 in bladder cancer (BC) remains unclear. METHODS: The SF3A3 mRN...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897952/ https://www.ncbi.nlm.nih.gov/pubmed/35248043 http://dx.doi.org/10.1186/s12935-022-02475-4 |
_version_ | 1784663540394622976 |
---|---|
author | Liu, Kai-Long Yin, Yue-Wei Lu, Bao-Sai Niu, Ya-Lin Wang, Dan-Dan Shi, Bei Zhang, Hong Guo, Ping-Ying Yang, Zhan Li, Wei |
author_facet | Liu, Kai-Long Yin, Yue-Wei Lu, Bao-Sai Niu, Ya-Lin Wang, Dan-Dan Shi, Bei Zhang, Hong Guo, Ping-Ying Yang, Zhan Li, Wei |
author_sort | Liu, Kai-Long |
collection | PubMed |
description | BACKGROUND: Abnormal expression of splicing factor 3A subunit 3 (SF3A3), a component of the spliceosome, has been confirmed to be related to the occurrence and development of various cancers. However, the expression and function of SF3A3 in bladder cancer (BC) remains unclear. METHODS: The SF3A3 mRNA and protein level were measured in clinical samples and cell lines by quantitative real-time PCR, Western blot and immunofluorescence staining. Evaluate the clinical correlation between SF3A3 expression and clinicopathological characteristics through statistical analysis in BC patients. The function of SF3A3 in BC cells was determined in vitro using MTT and colony analysis. Co-immunoprecipitation (CoIP) assay was used to detected E2F6 and KDM5C interaction. Luciferase reporter and chromatin immunoprecipitation (ChIP) were used to examine the relationship between E2F6/KDM5C and SF3A3 expression. RESULTS: In the present study, we demonstrated that expression of SF3A3 was elevated in BC tissue compared to the normal bladder tissue. Importantly, the upregulation of SF3A3 in patients was correlated with poor prognosis. Additionally, overexpression of SF3A3 promoted while depletion of SF3A3 reduced the growth of BC cells in vivo and in vitro. Data from the TCGA database and clinical samples revealed that hypomethylation of the DNA promoter leads to high expression of SF3A3 in BC tissue. We found that upregulation of lysine-specific demethylase 5C (KDM5C) promotes SF3A3 expression via hypomethylation of the DNA promoter. The transcription factor E2F6 interacts with KDM5C, recruits KDM5C to the SF3A3 promoter, and demethylates the GpC island of H3K4me2, leading to high SF3A3 expression and BC progression. CONCLUSIONS: The results demonstrated that depletion of the KDM5C/SF3A3 prevents the growth of BC in vivo and in vitro. The E2F6/KDM5C/SF3A3 pathway may be a potential therapeutic target for BC treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-022-02475-4. |
format | Online Article Text |
id | pubmed-8897952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88979522022-03-16 E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter Liu, Kai-Long Yin, Yue-Wei Lu, Bao-Sai Niu, Ya-Lin Wang, Dan-Dan Shi, Bei Zhang, Hong Guo, Ping-Ying Yang, Zhan Li, Wei Cancer Cell Int Primary Research BACKGROUND: Abnormal expression of splicing factor 3A subunit 3 (SF3A3), a component of the spliceosome, has been confirmed to be related to the occurrence and development of various cancers. However, the expression and function of SF3A3 in bladder cancer (BC) remains unclear. METHODS: The SF3A3 mRNA and protein level were measured in clinical samples and cell lines by quantitative real-time PCR, Western blot and immunofluorescence staining. Evaluate the clinical correlation between SF3A3 expression and clinicopathological characteristics through statistical analysis in BC patients. The function of SF3A3 in BC cells was determined in vitro using MTT and colony analysis. Co-immunoprecipitation (CoIP) assay was used to detected E2F6 and KDM5C interaction. Luciferase reporter and chromatin immunoprecipitation (ChIP) were used to examine the relationship between E2F6/KDM5C and SF3A3 expression. RESULTS: In the present study, we demonstrated that expression of SF3A3 was elevated in BC tissue compared to the normal bladder tissue. Importantly, the upregulation of SF3A3 in patients was correlated with poor prognosis. Additionally, overexpression of SF3A3 promoted while depletion of SF3A3 reduced the growth of BC cells in vivo and in vitro. Data from the TCGA database and clinical samples revealed that hypomethylation of the DNA promoter leads to high expression of SF3A3 in BC tissue. We found that upregulation of lysine-specific demethylase 5C (KDM5C) promotes SF3A3 expression via hypomethylation of the DNA promoter. The transcription factor E2F6 interacts with KDM5C, recruits KDM5C to the SF3A3 promoter, and demethylates the GpC island of H3K4me2, leading to high SF3A3 expression and BC progression. CONCLUSIONS: The results demonstrated that depletion of the KDM5C/SF3A3 prevents the growth of BC in vivo and in vitro. The E2F6/KDM5C/SF3A3 pathway may be a potential therapeutic target for BC treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-022-02475-4. BioMed Central 2022-03-05 /pmc/articles/PMC8897952/ /pubmed/35248043 http://dx.doi.org/10.1186/s12935-022-02475-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Primary Research Liu, Kai-Long Yin, Yue-Wei Lu, Bao-Sai Niu, Ya-Lin Wang, Dan-Dan Shi, Bei Zhang, Hong Guo, Ping-Ying Yang, Zhan Li, Wei E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter |
title | E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter |
title_full | E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter |
title_fullStr | E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter |
title_full_unstemmed | E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter |
title_short | E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter |
title_sort | e2f6/kdm5c promotes sf3a3 expression and bladder cancer progression through a specific hypomethylated dna promoter |
topic | Primary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897952/ https://www.ncbi.nlm.nih.gov/pubmed/35248043 http://dx.doi.org/10.1186/s12935-022-02475-4 |
work_keys_str_mv | AT liukailong e2f6kdm5cpromotessf3a3expressionandbladdercancerprogressionthroughaspecifichypomethylateddnapromoter AT yinyuewei e2f6kdm5cpromotessf3a3expressionandbladdercancerprogressionthroughaspecifichypomethylateddnapromoter AT lubaosai e2f6kdm5cpromotessf3a3expressionandbladdercancerprogressionthroughaspecifichypomethylateddnapromoter AT niuyalin e2f6kdm5cpromotessf3a3expressionandbladdercancerprogressionthroughaspecifichypomethylateddnapromoter AT wangdandan e2f6kdm5cpromotessf3a3expressionandbladdercancerprogressionthroughaspecifichypomethylateddnapromoter AT shibei e2f6kdm5cpromotessf3a3expressionandbladdercancerprogressionthroughaspecifichypomethylateddnapromoter AT zhanghong e2f6kdm5cpromotessf3a3expressionandbladdercancerprogressionthroughaspecifichypomethylateddnapromoter AT guopingying e2f6kdm5cpromotessf3a3expressionandbladdercancerprogressionthroughaspecifichypomethylateddnapromoter AT yangzhan e2f6kdm5cpromotessf3a3expressionandbladdercancerprogressionthroughaspecifichypomethylateddnapromoter AT liwei e2f6kdm5cpromotessf3a3expressionandbladdercancerprogressionthroughaspecifichypomethylateddnapromoter |